10-Q: Earth Science Tech Reports Strong Revenue Growth in Q2 2025, Driven by Pharmaceutical Sales

Earth Science Tech, Inc. reports a significant increase in revenue and profitability for the quarter ended September 30, 2024, driven by strong pharmaceutical sales.

Summary

• Earth Science Tech, Inc. reported a substantial increase in revenue for the three and six months ended September 30, 2024, compared to the same periods in 2023.
• Revenue for the three months ended September 30, 2024, was $8,519,047, a significant increase from $1,927,720 in the same period of 2023.
• For the six months ended September 30, 2024, revenue reached $17,087,965, compared to $2,147,654 in the first six months of 2023.
• The company's gross profit margin also improved, reaching 73% for the three months ended September 30, 2024, compared to 61% in the same period of 2023.
• Net income for the three months ended September 30, 2024, was $798,368, compared to $444,581 in the same period of 2023.
• Net income for the six months ended September 30, 2024, was $1,874,622, compared to $357,372 in the same period of 2023.
• The company repurchased 6,345,896 shares of its common stock for $922,795 during the six months ended September 30, 2024.
• The company completed the acquisition of Avenvi, LLC on October 1, 2024, for $1,058,788 and Mister Meds, LLC on October 3, 2024, for $54,200.

Sentiment

Score: 8

Explanation: The document shows strong financial performance with significant revenue and profit growth, strategic acquisitions, and a stock repurchase program. However, there are some concerns about increasing operating expenses and reliance on a few large customers.

Positives

• The company experienced a substantial increase in revenue, with a 342% increase in the three months ended September 30, 2024, compared to the same period in 2023.
• Gross profit margin improved significantly, indicating better cost management and pricing strategies.
• Net income increased substantially, demonstrating improved profitability.
• The company successfully repurchased a significant number of its shares, potentially increasing shareholder value.
• The acquisitions of Avenvi, LLC and Mister Meds, LLC expand the company's assets and market reach.
• The launch of Zoolzy diversifies the company's product offerings and targets a new market segment.
• The relocation to a larger office space supports the company's growth and expansion.

Negatives

• Salaries expense increased significantly to $3,605,954 for the three months ended September 30, 2024, due to new hires and executive compensation agreements.
• General and administrative expenses increased substantially to $1,259,422 for the three months ended September 30, 2024, due to area manager fees.
• Bank charges totaled $271,452 for the three months ended September 30, 2024, due to credit card processing fees.
• Marketing expenses increased to $152,520 for the three months ended September 30, 2024, as part of a strategic plan to increase sales.

Risks

• The company's rapid growth has led to increased operating expenses, including salaries and administrative costs.
• The company's reliance on a few large customers could pose a risk if those relationships change.
• The company's cash balance exceeds federally insured limits, which could pose a risk.
• The company's new executive compensation agreement is tied to net profit increases, which could lead to renegotiation if targets are not met.
• The company's expansion into new markets and acquisitions may present integration and operational challenges.

Future Outlook

The company intends to expand its offerings to include over-the-counter products and continue to pursue licenses in additional states for its pharmacy operations. The company also plans to continue its stock repurchase program.

Management Comments

• Management believes the increase in revenue is primarily due to an increase of sales through new accounts.
• Management has contemplated the increase in marketing expenses as part of the strategic plan to increase sales.
• Management does not believe that legal matters will have a material adverse effect on the company's financial position.
• Management has concluded that the company's disclosure controls and procedures were effective as of September 30, 2024.
• Management has concluded that the company's internal control over financial reporting was reasonably effective as of the Evaluation Date.

Industry Context

The company's growth in the pharmaceutical and telemedicine sectors aligns with broader trends in the healthcare industry, where there is increasing demand for convenient and accessible healthcare solutions. The expansion into pet and wildlife medications also taps into a growing market segment.

Comparison to Industry Standards

• The company's revenue growth significantly exceeds the average growth rate of many small-cap pharmaceutical and telemedicine companies.
• The gross profit margin of 73% is competitive within the pharmaceutical compounding industry, suggesting efficient operations and pricing.
• The company's net income growth indicates strong financial performance compared to many peers in the sector.
• The company's stock repurchase program is a positive sign for investors, indicating management's confidence in the company's future prospects.
• The acquisitions of Avenvi and Mister Meds are strategic moves to expand the company's asset base and market reach, similar to strategies employed by other growing healthcare companies.
• The launch of Zoolzy is a unique approach to diversify revenue streams, which is not commonly seen in all pharmaceutical companies.

Related Party Transactions

• The company pays employee compensation for Giorgio R. Saumat and Mario Tabraue to their respective, solely owned LLCs.
• The company reimbursed Point 96 Consulting LLC for consulting services, marketing, and SG&A in the amount of $439,000.
• The company paid Avenvi LLC $273,776 for stock repurchases.
• The company acquired Avenvi, LLC from Giorgio R. Saumat and Mister Meds, LLC from Mario G. Tabraue.

Stakeholder Impact

• Shareholders will benefit from the increased profitability and stock repurchase program.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to a wider range of products and services.
• Suppliers may benefit from increased orders and business opportunities.
• Creditors may view the company as a more stable and reliable borrower.

Next Steps

• The company will continue to pursue licenses in additional states for its pharmacy operations.
• The company will expand its offerings to include over-the-counter products.
• The company will continue its stock repurchase program.
• The company will integrate the newly acquired businesses, Avenvi and Mister Meds.
• The company will continue to develop and market its new pet and wildlife medication brand, Zoolzy.

Key Dates

Keywords

pharmaceuticals, telemedicine, compounding pharmacy, revenue growth, net income, acquisitions, stock repurchase, healthcare, wellness, Zoolzy